Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep;188(9):2672-2683.
doi: 10.1002/ajmg.a.62860. Epub 2022 Jun 9.

Understanding barriers to diagnosis in a rare, genetic disease: Delays and errors in diagnosing schwannomatosis

Affiliations
Review

Understanding barriers to diagnosis in a rare, genetic disease: Delays and errors in diagnosing schwannomatosis

Vanessa L Merker et al. Am J Med Genet A. 2022 Sep.

Abstract

Diagnosis of rare, genetic diseases is challenging, but conceptual frameworks of the diagnostic process can guide quality improvement initiatives. Using the National Academy of Medicine diagnostic framework, we assessed the extent of, and reasons for diagnostic delays and diagnostic errors in schwannomatosis, a neurogenetic syndrome characterized by nerve sheath tumors and chronic pain. We reviewed the medical records of 97 people with confirmed or probable schwannomatosis seen in two US tertiary care clinics. Time-to-event analysis revealed a median time from first symptom to diagnosis of 16.7 years (95% CI, 7.5-26.0 years) and median time from first medical consultation to diagnosis of 9.8 years (95% CI, 3.5-16.2 years). Factors associated with longer times to diagnosis included initial signs/symptoms that were intermittent, non-specific, or occurred at younger ages (p < 0.05). Thirty-six percent of patients were misdiagnosed; misdiagnoses were of underlying genetic condition (18.6%), pain etiology (16.5%), and nerve sheath tumor presence/pathology (11.3%) (non-mutually exclusive categories). One-fifth (19.6%) of patients had a clear missed opportunity for genetics workup that could have led to an earlier schwannomatosis diagnosis. These results suggest that interventions in clinician education, genetic testing availability, expert review of pathology findings, and automatic triggers for genetics referrals may improve diagnosis of schwannomatosis.

Keywords: delayed diagnosis; diagnostic errors; missed diagnosis; rare disease; schwannomatosis.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Vanessa Merker reports consulting income from the Neurofibromatosis Network. Justin Jordan reports consulting income from Navio Theragnostics, CereXis, Recursion, Health2047; <1% stock ownership in Navio Theragnostics; Royalties from Elsevier. Jaishri Blakeley has served as a paid consultant for Astella Pharma, Abbvie, TriAct/BiPar Sciences and has had research support from GlaxoSmithKlein, Bristol Meyer Squibb, and AstraZeneca. Scott Plotkin is co-founder of NFlection Therapeutics and NF2 Therapeutics; serves on the Scientific Advisory Board and has stock in SonALAsense; and consults for Akouos.

Figures

Figure 1
Figure 1
Conceptual Model of the Diagnostic Process (Reprinted with Permission from the National Academy of Medicine)
Figure 2.
Figure 2.
Key Diagnostic Timepoints and Diagnostic Intervals
Figure 3.
Figure 3.
Timeliness of Schwannomatosis Diagnosis Probability of receiving a schwannomatosis diagnosis based on time to diagnosis of confirmed schwannomatosis patients (n=64, red); time to diagnosis communication in confirmed patients with documented communication (n=54, blue); and total time spent in the diagnostic process for all the entire cohort (n=97, green).

References

    1. Ferreira CR. The burden of rare diseases. Am J Med Genet A 2019;179(6):885–892. (In eng). DOI: 10.1002/ajmg.a.61124. - DOI - PubMed
    1. EURORDIS. The Voice of 12,000 Patients: Experiences and Expectations of Rare Disease Patients on Diagnosis and Care in Europe. 2009. (http://www.eurordis.org/IMG/pdf/voice_12000_patients/EURORDISCARE_FULLBO....
    1. Shire Genetic Therapies. Rare Disease Impact Report: Insights from patients and the medical community. April 2013. Available at https://globalgenes.org/wp-content/uploads/2013/04/ShireReport-1.pdf.
    1. Bogart KR, Irvin VL. Health-related quality of life among adults with diverse rare disorders. Orphanet J Rare Dis 2017;12(1):177. DOI: 10.1186/s13023-017-0730-1. - DOI - PMC - PubMed
    1. Bryson B, Bogart K, Atwood M, et al. Navigating the unknown: A content analysis of the unique challenges faced by adults with rare diseases. J Health Psychol 2019:1359105319828150. DOI: 10.1177/1359105319828150. - DOI - PubMed

Publication types

Supplementary concepts